Skip to main content
AmigoFish

Durvalumab + Enfortumab vedotin FDA Approval for Muscle Invasive Bladder Cancer (MIBC): VOLGA

From Oncology Brothers: Practice-Changing Cancer Discussions · · 25 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

In this episode of the Oncology Brothers podcast, we welcomed Dr. Petros Grivas from Fred Hutch Cancer Center to discuss the recent FDA approval of the durvalumab plus enfortumab vedotin (EV) regimen for cisplatin-ineligible muscle-invasive bladder cancer (MIBC), based on the findings from the VOLGA trial.

Join us as we explored:

- The evolution of treatment standards for MIBC over the past 2 years

- Key insights from the VOLGA trial, including study design, findings, and clinical implications

- The significance of event-free survival (EFS) and overall survival (OS) rates in the context of this new regimen

- The balance between overtreatment and undertreatment in patient care

- The side effect profiles of durvalumab and enfortumab vedotin, and how they impact treatment decisions

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

•⁠ ⁠X/Twitter: https://x.com/oncbrothers

•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers

•⁠ Website: https://oncbrothers.com/

Don't forget to like, subscribe, and share your thoughts in the comments!

#BladderCancer, #MIBC, #Durvalumab, #EnfortumabVedotin, #VOLGATrial

Back to Oncology Brothers: Practice-Changing Cancer Discussions · Report a problem